Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith & Nephew plc reports new share-based awards for senior leaders under three incentive plans. On 1 April 2026, the CEO and CFO deferred 50% of their 2025 annual bonuses into share awards under the Deferred Share Bonus Plan, using a price of £12.744 per share, with vesting scheduled for 15 March 2029.
Additional performance share awards were granted under the Global Share Plan 2020, also at £12.744 per share, with vesting in 2029 subject to performance measured from 1 January 2026 to 31 December 2028. Further time-based awards were made under the Restricted Share Plan 2024, vesting in equal annual tranches over three years, with the CEO and CFO awards subject to a judgement-based underpin linked to financial, regulatory, ESG, safety and reputational outcomes.
Smith & Nephew plc reports its updated share capital and voting rights position. As at 31 March 2026, the company has 877,733,750 ordinary shares of US20¢ each in issue, including 23,761,952 held in treasury. The issued share capital with voting rights consists of 853,971,798 ordinary shares, each carrying one vote. Shareholders are directed to use 853,971,798 as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reported that on 23 March 2026 multiple executive and senior managers had share awards vest under its Global Share Plans 2010/2020 and Restricted Share Plan 2024.
Ordinary shares were delivered and portions sold on the London Stock Exchange at £11.938637 to cover tax liabilities, with the balance retained by each participant.
Smith & Nephew reports that funds controlled by Cevian Capital II G.P. Limited now hold 10.094356% of its voting rights, equal to 85,790,848 voting rights. This more than doubles their previously notified position of 5.021046%. The stake is held legally by Aurora Nominees Limited on behalf of UBS AG as custodian.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.
Smith & Nephew delivered stronger full-year 2025 results, with revenue rising to $6,164m from $5,810m and operating profit increasing to $794m from $657m. Attributable profit grew to $625m, lifting basic earnings per share to 72.1¢ from 47.2¢.
Growth was broad-based: Orthopaedics revenue reached $2,437m, Sports Medicine & ENT $1,934m, and Advanced Wound Management $1,793m. Established Markets generated $5,161m of revenue and Emerging Markets $1,003m, with US revenue at $3,306m.
Cash generation was robust, with net cash from operating activities of $1,285m. The company invested $433m in capital expenditure and paid equity dividends of $330m, while also spending $502m on share repurchases. Year-end cash and cash equivalents were $553m, and net debt excluding leases was $2,543m.
Deloitte issued unqualified opinions on both the financial statements and internal control over financial reporting. A key audit focus was the valuation of the excess and obsolescence provision for US orthopaedics inventory, reflecting judgement around future product demand.
Smith+Nephew plc reports that its Chief Executive Officer, Deepak Nath, will join the Board of Reckitt Benckiser Group plc as an independent Non-Executive Director with effect from 1 April 2026. The appointment is disclosed in line with UK Listing Rule 6.4.9R(2).
Smith+Nephew is a global medical technology business focused on repairing, regenerating and replacing soft and hard tissue. It employs around 17,000 people, operates in more than 100 countries and generated annual sales of $6.2 billion in 2025 across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Smith & Nephew plc has updated investors on its voting rights and share capital. As at 28 February 2026, the company had 877,724,845 ordinary shares of US20¢ each in issue, including 27,835,540 shares held in treasury. Because treasury shares do not carry voting rights, shareholders have a total of 849,889,305 voting shares to use as the denominator when assessing whether they must notify the regulator of their holdings or changes in their stake.